Climb Bio (CLYM) Consolidated Net Income (2020 - 2026)

Climb Bio's Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$46.1 million for Q1 2026.

• Quarterly Consolidated Net Income fell 116.57% year-over-year to -$46.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$98.3 million (down 0.81% YoY) and the FY2025 annual result came in at -$71.3 million, up 30.37% from the prior year.
• Consolidated Net Income was -$46.1 million for Q1 2026 at Climb Bio, down from -$29.2 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$2.7 million in Q1 2024 and bottomed at -$57.7 million in Q2 2024.
• A 5-year average of -$20.3 million and a median of -$17.5 million in 2022 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2024 — Consolidated Net Income surged 89.04% — and 2025, when it tumbled 676.95%.
• Climb Bio's Consolidated Net Income stood at -$25.6 million in 2022, then advanced by 3.62% to -$24.6 million in 2023, then soared by 64.92% to -$8.6 million in 2024, then slumped by 237.93% to -$29.2 million in 2025, then slumped by 57.73% to -$46.1 million in 2026.
• Business Quant data shows CLYM's Consolidated Net Income at -$46.1 million in Q1 2026, -$29.2 million in Q4 2025, and -$14.5 million in Q3 2025.